Literature DB >> 23744029

Limited generalisability of UPLIFT findings to clinical practice.

Steven Walker1, James Fingleton, Mark Weatherall, Richard Beasley.   

Abstract

BACKGROUND: The findings of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study may be poorly generalisable to tiotropium use in clinical practice.
METHODS: An audit of 226 patients admitted to Wellington Hospital with a chronic obstructive pulmonary disease exacerbation determined the proportion of patients prescribed tiotropium on discharge that would have been ineligible for inclusion in the UPLIFT study.
RESULTS: Among 100 patients prescribed tiotropium, 38/100; 38% (95% CI 28.5% to 48.3%) would have been ineligible for UPLIFT at the time of the hospital discharge due to recent cardiovascular comorbidity or moderate to severe renal impairment.
CONCLUSIONS: The UPLIFT findings have limited generalisability to over a third of patients prescribed tiotropium following a hospital admission with a chronic obstructive pulmonary disease exacerbation in New Zealand.

Entities:  

Keywords:  COPD Pharmacology

Mesh:

Substances:

Year:  2013        PMID: 23744029     DOI: 10.1136/thoraxjnl-2013-203724

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in High-Risk Patients With Chronic Obstructive Pulmonary Disease: The ASCENT-COPD Randomized Clinical Trial.

Authors:  Robert A Wise; Kenneth R Chapman; Benjamin M Scirica; Deepak L Bhatt; Sami Z Daoud; Sofia Zetterstrand; Colin Reisner; Esther Garcia Gil
Journal:  JAMA       Date:  2019-05-07       Impact factor: 56.272

Review 2.  Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease.

Authors:  Marc Miravitlles; David Price; Klaus F Rabe; Hendrik Schmidt; Norbert Metzdorf; Bartolome Celli
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-16

3.  Cardiac safety of tiotropium in patients with cardiac events: a retrospective analysis of the UPLIFT® trial.

Authors:  Donald P Tashkin; Inge Leimer; Norbert Metzdorf; Marc Decramer
Journal:  Respir Res       Date:  2015-06-02

4.  Eligibility of real-life patients with COPD for inclusion in RCTs: a commentary.

Authors:  Salvatore Battaglia; Nicola Scichilone
Journal:  Respir Res       Date:  2017-01-05

Review 5.  Defining severe obstructive lung disease in the biologic era: an endotype-based approach.

Authors:  Richard J Martin; Elisabeth H Bel; Ian D Pavord; David Price; Helen K Reddel
Journal:  Eur Respir J       Date:  2019-11-21       Impact factor: 16.671

6.  The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease.

Authors:  Nawar Diar Bakerly; Dominy Browning; Isabelle Boucot; Jodie Crawford; Sheila McCorkindale; Norman Stein; John P New
Journal:  Ther Adv Respir Dis       Date:  2021 Jan-Dec       Impact factor: 4.031

7.  Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists.

Authors:  Cristina Rebordosa; Estel Plana; Annalisa Rubino; Jaume Aguado; David Martinez; Alejhandra Lei; Sami Daoud; Nuria Saigi-Morgui; Susana Perez-Gutthann; Elena Rivero-Ferrer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-08-02

8.  Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy.

Authors:  David M G Halpin; Marjan Kerkhof; Joan B Soriano; Helga Mikkelsen; David B Price
Journal:  Respir Res       Date:  2016-09-23

9.  One-year mortality associated with COPD treatment: a comparison of tiotropium and long-acting beta2-agonists in three Italian regions: results from the OUTPUL study.

Authors:  Ursula Kirchmayer; Silvia Cascini; Nera Agabiti; Mirko Di Martino; Lisa Bauleo; Giulio Formoso; Claudio Voci; Riccardo Pistelli; Elisabetta Patorno; Marina Davoli
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-29       Impact factor: 2.890

10.  Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis.

Authors:  Chuchu Zhang; Meng Zhang; Yalei Wang; Huaiyu Xiong; Qiangru Huang; Tiankui Shuai; Jian Liu
Journal:  J Investig Med       Date:  2021-08-06       Impact factor: 2.895

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.